News Archive

Discovery and validation of a blood-based protein signature for early detection of mesothelioma

A multi-institute team of researchers led by scientists at the NYU Langone Medical Center and SomaLogic, Inc., announced today the discovery and validation of a panel of 13 blood-based protein biomarkers that can detect malignant mesothelioma in even the early stages of this rare but deadly cancer. The work, which is based on a new protein measurement technology developed by SomaLogic, is published today in the open-access scientific journal PLOS ONE.

read more

SomaLogic scientists publish protein biomarker analysis of lung cancer

In a scientific paper published today in the journal PLoS ONE, researchers from SomaLogic and the University of Washington in Seattle describe the first application of the SOMAscanTM proteomic assay technology to tissue samples. Working with both tumor and non-cancerous lung samples from patients with non-small cell lung cancer (NSCLC), they identified significant expression changes in 36 proteins, including 13 proteins not previously associated with the disease. These findings reveal significant new information about the biology underlying NSCLC, and have implications for improving early diagnosis and treatment.

read more

SomaLogic and HUNT Biosciences announce CV collaboration

HUNT Biosciences and SomaLogic, Inc., today announced a new collaboration to advance the clinical use of protein biomarkers, with an initial focus on the validation of biomarkers for the prediction of cardiovascular events such as strokes, heart attacks, and heart failure.

read more

SomaLogic receives Gates Foundation Grand Challenges Tuberculosis Biomarkers Grant

SomaLogic, Inc., announced today that it will receive a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation’s Grand Challenges in Global Health program, an initiative that seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world. Urs Ochsner, head of the Infectious Diseases Research Group at SomaLogic, will pursue an innovative research project to identify and validate TB biomarkers, titled SOMAmer-based detection of tuberculosis biomarkers.

read more

SomaLogic announces collaboration with Novartis

SomaLogic announces collaboration with Novartis 10/18/2011 SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development Powerful proteomic technology to be applied to biomarker discovery,...

read more

SomaLogic and New England Biolabs Agree on SOMAmer Use in PCR Products

SomaLogic, Inc. and New England Biolabs, Inc. (NEB) announced today that they have entered into an exclusive licensing agreement whereby SomaLogic will provide specific SOMAmers as critical and unique reagents in several current and future NEB nucleic acid amplification and polymerase chain reaction (PCR) products.

read more

Emerald and SomaLogic announce collaboration to image SOMAmer-protein complexes

Emerald BioStructures, a leading provider of integrated structural biology services, and SomaLogic, Inc., a diagnostics and biomarker discovery company, today announced that they have entered into a strategic collaboration for the structure-based design of chemically modified DNA aptamers (“SOMAmers”) and small molecule therapeutics, based on crystal structures of important protein targets bound to high affinity SOMAmers.

read more